[pending] XOLAIR (OMALIZUMAB)
Pending LLM rewrite. Source: FDA_DRUG D-0572-2025.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
The recalled product
- Product
- XOLAIR (OMALIZUMAB)
- Brand
- XOLAIR
- Manufacturer
- Cardinal Health Inc.
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 3630004
- Expires: 10/31/2025.
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · XOLAIR
- ModerateGenentech Xolair Injection Recalled for Failed Stability Specifications
FDA (Drugs) · 2021-07-14
Same category
- ModerateQuality Choice Earwax Removal Kit Carbamide Peroxide Subpotent Drug Recall
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- ModerateFamily Wellness Carbamide Peroxide Earwax Removal Kit Subpotent Drug
FDA (Drugs) · 2026-07-22
- ModerateClinere Ear Wax Remover Recalled for Subpotent Carbamide Peroxide
FDA (Drugs) · 2026-07-22